Nevertheless, investigators retained the discretion to use a GnRH agonist trigger below the protocol-defined threshold if the patient was deemed to be at increased risk of developing OHSS based on their clinical judgement. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.